Investigation into the binding domains of platelet factor 4 unlocks new avenues for the design and synthesis of selective sulfated pseudo-tetrasaccharide aminoglycoside ligands
Structure–activity relationship (SAR) study published in European journal of medicinal chemistry (2025)
Abstract
Platelet factor 4 (PF4) is a natural chemokine that binds to negatively charged glycosaminoglycans (GAGs), including the anticoagulant heparin. The formation of the PF4-heparin complex elicits an immune response that results in platelet activation, leading to serious thrombotic complications. This study explores the structure-activity relationships (SAR) of sulfated pseudo-tetrasaccharide aminoglycoside ligands. The binding interactions of these synthetically designed compounds with heparanase (HPSE) and PF4 were systematically elucidated. Through computational design, a library of sulfated aminoglycoside ligands was synthesized in 10-13 steps from readily available paromomycin and neomycin. The SAR studies revealed that hydroxyl-capped ligands interacted with the fondaparinux-binding domain of PF4, while hydrophobic-capped ligands bound to the heparin-binding domain. Notably, steric hindrance imposed by hydrophobic groups impedes the binding of the ligands to PF4's shallow binding site. In contrast, these hydrophobic-capped ligands demonstrated a strong binding affinity for HPSE. The most selective ligands reduced the viability of HPSE-overexpressing cancer cells, highlighting their potential efficacy in modulating the enzymatic activity of HPSE. This SAR study provides a foundational framework for the design of sulfated aminoglycoside-based therapeutics with minimized adverse effects associated with PF4.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Structure-activity studies of sulfated pseudo-tetrasaccharide aminoglycoside ligands found hydroxyl-capped compounds bound platelet factor 4's fondaparinux-binding domain while hydrophobic-capped compounds bound its heparin-binding domain and showed strong heparanase affinity; the most selective ligands reduced viability of heparanase-overexpressing cancer cells.
Why This Matters for Hirudotherapy
This medicinal-chemistry study mapped how synthetically designed sulfated pseudo-tetrasaccharide aminoglycoside ligands bind platelet factor 4 (PF4) and heparanase (HPSE), reporting that hydroxyl-capped ligands engaged PF4's fondaparinux-binding domain while hydrophobic-capped ligands instead bound the heparin-binding domain and HPSE, with the most selective ligands reducing viability of HPSE-overexpressing cancer cells. For hirudotherapy the connection is contextual rather than direct: the PF4-heparin complex described here is the immunological trigger of heparin-associated platelet activation and thrombotic complications, which is precisely the heparin liability that motivates interest in mechanistically distinct, non-heparin anticoagulants such as the leech-derived direct thrombin inhibitor hirudin. This is preclinical, computational and in-vitro work on engineered small molecules with no leech-derived compound or patient data, so it informs the broader anticoagulant-safety landscape only as background and cannot be read as evidence about leech therapy itself.
Citation
Reference (Vancouver style)
Philip L, Abdulsalam H, Singh K, Nguyen HM. Investigation into the binding domains of platelet factor 4 unlocks new avenues for the design and synthesis of selective sulfated pseudo-tetrasaccharide aminoglycoside ligands. Eur J Med Chem. 2025;295:117792. doi:10.1016/j.ejmech.2025.117792. PMID: 40424780
Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.
Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026